

Louis B Nabors

List of Publications by Citations

Source: <https://exaly.com/author-pdf/443248/louis-b-nabors-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

9,470
citations

52
h-index

95
g-index

174
ext. papers

10,921
ext. citations

5.2
avg, IF

5.51
L-index

#	Paper	IF	Citations
160	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1100-8	21.7	629
159	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1373-1385	21.7	518
158	Human cytomegalovirus infection and expression in human malignant glioma. <i>Cancer Research</i> , 2002 , 62, 3347-50	10.1	466
157	Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3212-8	2.2	392
156	Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5610-7	2.2	384
155	Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. <i>Clinical Cancer Research</i> , 2010 , 16, 2443-9	12.9	347
154	Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. <i>Journal of Clinical Investigation</i> , 2001 , 108, 1657-65	15.9	338
153	A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. <i>Molecular Therapy</i> , 2004 , 10, 958-66	11.7	332
152	Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. <i>Molecular Therapy</i> , 2009 , 17, 199-207	11.7	278
151	Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1651-7	2.2	250
150	A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. <i>Molecular Therapy</i> , 2014 , 22, 1048-55	11.7	170
149	Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. <i>Clinical Cancer Research</i> , 2004 , 10, 5643-6	12.9	165
148	Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3644-50	2.2	162
147	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1225-35	5.9	152
146	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. <i>Neuro-Oncology</i> , 2015 , 17, 708-17	1	148
145	Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. <i>Clinical Cancer Research</i> , 2008 , 14, 4694-704	12.9	140
144	SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. <i>Science Translational Medicine</i> , 2015 , 7, 289ra86	17.5	137

143	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 731-9 ^{2.2}		108
142	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1331-1345	7.3	106
141	Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis. <i>Journal of Neuroscience Methods</i> , 1988 , 26, 1-23	3	105
140	The RNA-binding protein HuR promotes glioma growth and treatment resistance. <i>Molecular Cancer Research</i> , 2011 , 9, 648-59	6.6	101
139	The ELAV RNA-stability factor HuR binds the 5' untranslated region of the human IGF-1R transcript and differentially represses cap-dependent and IRES-mediated translation. <i>Nucleic Acids Research</i> , 2005 , 33, 2962-79	20.1	98
138	A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). <i>Cancer</i> , 2012 , 118, 5601-7	6.4	95
137	Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. <i>Cancer Research</i> , 2003 , 63, 4181-7	10.1	95
136	The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. <i>Molecular and Cellular Biology</i> , 2008 , 28, 6632-45	4.8	91
135	Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. <i>Neuro-Oncology</i> , 2004 , 6, 21-7	1	86
134	Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. <i>Cancer Research</i> , 2005 , 65, 5535-43	10.1	86
133	A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. <i>Clinical Cancer Research</i> , 2013 , 19, 900-8	12.9	85
132	Medical decision-making capacity in patients with malignant glioma. <i>Neurology</i> , 2009 , 73, 2086-92	6.5	85
131	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. <i>Human Gene Therapy Clinical Development</i> , 2016 , 27, 69-78	3.2	83
130	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017 , 19, 1119-1126	1	82
129	Cilengitide: an RGD pentapeptide α and β integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , 2011 , 7, 339-54	3.6	82
128	IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. <i>International Journal of Cancer</i> , 2005 , 113, 911-9	7.5	81
127	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1209-1217	3.5	80
126	Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 65, 1192-9	4	79

125	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 430-9	1	78
124	ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018 , 20, vi5-vi5 ¹		78
123	NIMG-13. SEGMENTATION AND VOLUMETRIC ANALYSIS IMPROVES DETECTION OF PROGRESSION IN LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018 , 20, vi178-vi178	1	78
122	ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 [FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi15-vi15	1	78
121	Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. <i>Journal of Magnetic Resonance Imaging</i> , 2004 , 20, 913-22	5.6	73
120	Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. <i>Cancer Research</i> , 2018 , 78, 3002-3013	10.1	71
119	Cancer susceptibility variants and the risk of adult glioma in a US case-control study. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 535-42	4.8	68
118	Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2011 , 55, 77-81	1.7	64
117	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013 , 15, 490-6	1	63
116	Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 95-103	4.8	63
115	A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 639-46	4.8	62
114	Distress and quality of life in primary high-grade brain tumor patients. <i>Supportive Care in Cancer</i> , 2009 , 17, 793-9	3.9	62
113	Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 61-72	4.8	59
112	Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1809-1816 ⁵⁹	12.9	59
111	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRVIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1586-1594 ⁹	12.9	56
110	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019 , 21, 106-114	1	56
109	Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. <i>Journal of Autoimmunity</i> , 1999 , 13, 435-43	15.5	53
108	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , 2016 , 7, 15018-32	3.3	49

107	Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR): implications for impaired post-transcriptional regulation of vascular endothelial growth factor. <i>Journal of Biological Chemistry</i> , 2009 , 284, 33989-98	5.4	48
106	A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. <i>Archives of Neurology</i> , 2010 , 67, 313-9		47
105	Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2009 , 11, 357-67	1	46
104	ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2009-2009	2.2	45
103	Ipilimumab-induced encephalopathy with a reversible splenic lesion. <i>Cancer Immunology Research</i> , 2015 , 3, 598-601	12.5	44
102	High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. <i>Magnetic Resonance in Medicine</i> , 2009 , 61, 615-25	4.4	41
101	Implementation and utilization of the molecular tumor board to guide precision medicine. <i>Oncotarget</i> , 2017 , 8, 57845-57854	3.3	41
100	Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). <i>Journal of Neuro-Oncology</i> , 2006 , 80, 261-74	4.8	40
99	Quantitative immunocytochemistry using an image analyzer. II. Concentration standards for transmitter immunocytochemistry. <i>Journal of Neuroscience Methods</i> , 1988 , 26, 25-34	3	40
98	Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function. <i>Journal of Biological Chemistry</i> , 2012 , 287, 32277-87	5.4	38
97	Reproductive factors and risk of primary brain tumors in women. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 297-304	4.8	37
96	The role of Src family kinases in growth and migration of glioma stem cells. <i>International Journal of Oncology</i> , 2014 , 45, 302-10	4.4	37
95	Cognition in patients with newly diagnosed brain metastasis: profiles and implications. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 179-85	4.8	35
94	Circadian pathway genes in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2014 , 25, 25-32	2.8	35
93	Anthropometric factors in relation to risk of glioma. <i>Cancer Causes and Control</i> , 2013 , 24, 1025-31	2.8	33
92	Rare TP53 genetic variant associated with glioma risk and outcome. <i>Journal of Medical Genetics</i> , 2012 , 49, 420-1	5.8	33
91	An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2012 , 23, 1443-9	2.8	32
90	HuR, a novel target of anti-Hu antibodies, is expressed in non-neural tissues. <i>Journal of Neuroimmunology</i> , 1998 , 92, 152-9	3.5	32

89	Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. <i>Neuro-Oncology</i> , 2011 , 13, 1324-30	1	31
88	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2017 , 19, 845-852	1	30
87	Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. <i>American Journal of Transplantation</i> , 2009 , 9, 1243-8	8.7	30
86	Prediagnostic body weight and survival in high grade glioma. <i>Journal of Neuro-Oncology</i> , 2013 , 114, 79-84.8	4.8	29
85	Capacity to consent to research participation in adults with malignant glioma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3844-50	2.2	28
84	An Update on Neurofibromatosis Type 1-Associated Gliomas. <i>Cancers</i> , 2020 , 12,	6.6	28
83	Hu antigen R (HuR) multimerization contributes to glioma disease progression. <i>Journal of Biological Chemistry</i> , 2017 , 292, 16999-17010	5.4	27
82	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019 , 21, 1498-1508	1	25
81	Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. <i>Clinical Cancer Research</i> , 2010 , 16, 2890-8	12.9	25
80	Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. <i>Neuro-Oncology</i> , 2008 , 10, 608-16	1	25
79	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. <i>Molecular Cancer Therapeutics</i> , 2002 , 1, 1139-45	6.1	25
78	Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells. <i>Cancer Biology and Therapy</i> , 2019 , 20, 979-988	4.6	24
77	Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?. <i>Journal of Neuro-Oncology</i> , 2018 , 138, 163-171	4.8	24
76	Repeatability of F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 393-398	8.9	24
75	Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. <i>Nature Communications</i> , 2020 , 11, 4660	17.4	24
74	1p/19q chromosome deletions in metastatic oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2006 , 80, 203-7	4.8	21
73	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	19
72	Complementary therapy and survival in glioblastoma. <i>Neuro-Oncology Practice</i> , 2015 , 2, 122-126	2.2	19

71	Capacity of patients with brain metastases to make treatment decisions. <i>Psycho-Oncology</i> , 2015 , 24, 1448-55	3.9	18
70	Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth. <i>Journal of Neuro-Oncology</i> , 2013 , 113, 195-205	4.8	18
69	SSBP2 variants are associated with survival in glioblastoma patients. <i>Clinical Cancer Research</i> , 2012 , 18, 3154-62	12.9	18
68	The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. <i>Neurocase</i> , 2017 , 23, 287-291	0.8	17
67	Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 361-70	4.8	17
66	IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015 , 17, v109.1-v109	1	17
65	Analysis of the 5Rend of the mouse Elavl1 (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organization. <i>Gene</i> , 2000 , 242, 125-31	3.8	16
64	Role of MRI in primary brain tumor evaluation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1561-8	7.3	14
63	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. <i>International Journal of Cancer</i> , 2020 , 146, 739-748	7.5	14
62	Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3186-92	2.2	13
61	Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor. <i>Neuro-Oncology Practice</i> , 2015 , 2, 13-19	2.2	13
60	Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 375-81	4.8	13
59	Treatment of adults with recurrent malignant glioma. <i>Expert Review of Neurotherapeutics</i> , 2005 , 5, 509-14	4.3	13
58	Brain tumor risk according to germ-line variation in the MLLT10 locus. <i>European Journal of Human Genetics</i> , 2015 , 23, 132-4	5.3	12
57	Early life exposures and the risk of adult glioma. <i>European Journal of Epidemiology</i> , 2013 , 28, 753-8	12.1	12
56	Primary central nervous system angiosarcoma: two case reports. <i>Journal of Medical Case Reports</i> , 2012 , 6, 251	1.2	12
55	Individualized screening trial of innovative glioblastoma therapy (INSIGHt).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2079-TPS2079	2.2	12
54	Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2027-2027	2.2	12

53	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020 , 22, 601-612	1	12
52	Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment. <i>Journal of Cancer Science & Therapy</i> , 2018 , 10, 190-197	5	12
51	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019 , 85, E607-E608	3.2	10
50	Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 585-93	4.8	10
49	Growth factor dependent regulation of centrosome function and genomic instability by HuR. <i>Biomolecules</i> , 2015 , 5, 263-81	5.9	10
48	SWI/SNF gene variants and glioma risk and outcome. <i>Cancer Epidemiology</i> , 2013 , 37, 162-5	2.8	10
47	Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. <i>PLoS Medicine</i> , 2019 , 16, e1002810	11.6	9
46	Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. <i>Neuro-Oncology</i> , 2020 , 22, 1422-1424	1	9
45	Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 1227-30	3	9
44	Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2058-2058	2.2	9
43	Analgesic use and the risk of primary adult brain tumor. <i>European Journal of Epidemiology</i> , 2016 , 31, 917-921	2.5	8
42	Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain Metastases. <i>Journal of the International Neuropsychological Society</i> , 2015 , 21, 412-8	3.1	8
41	Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. <i>Neuro-Oncology Practice</i> , 2014 , 1, 172-177	2.2	8
40	Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors. <i>Cancer Research</i> , 2021 , 81, 2220-2233	10.1	8
39	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2018 , 101, 95-104	7.5	7
38	Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuR. <i>Journal of Neuroimmunology</i> , 2012 , 246, 34-7	3.5	7
37	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2003-2003	2.2	7
36	Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2017-2017	2.2	7

35	Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 123-31	4.8	6
34	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019 , 25, 73-79	12.9	6
33	Toenail iron, genetic determinants of iron status, and the risk of glioma. <i>Cancer Causes and Control</i> , 2013 , 24, 2051-8	2.8	6
32	ELAVL1 Role in Cell Fusion and Tunneling Membrane Nanotube Formations with Implication to Treat Glioma Heterogeneity. <i>Cancers</i> , 2020 , 12,	6.6	6
31	Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma. <i>International Journal of Surgical Pathology</i> , 2016 , 24, 753-756	1.2	5
30	Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2542-2542	2.2	5
29	Older age at the completion of linear growth is associated with an increased risk of adult glioma. <i>Cancer Causes and Control</i> , 2017 , 28, 709-716	2.8	4
28	Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma. <i>Scientific Reports</i> , 2019 , 9, 10861	4.9	4
27	An early feasibility study of the Nativis Voyager device in patients with recurrent glioblastoma: first cohort in US. <i>CNS Oncology</i> , 2019 , 8, CNS30	4	4
26	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
25	A novel technique to quantify glioma tumor invasion using serial microscopy sections. <i>Journal of Neuroscience Methods</i> , 2006 , 153, 183-9	3	3
24	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2019 , 20, 1123-1131	1	3
23	Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2055-2055	2.2	2
22	Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2005-2005	2.2	2
21	Catheter placement selection for convection-enhanced delivery of therapeutic agents to brain tumors. <i>F1000Research</i> , 9 , 1415	3.6	2
20	The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.. <i>Advanced Drug Delivery Reviews</i> , 2021 , 181, 114082	18.5	2
19	Management of Central Nervous System Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 579-582	7.3	2
18	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2

17	ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi14-vi14	1	2
16	SRI-42127, a novel small molecule inhibitor of the RNA regulator HuR, potently attenuates glial activation in a model of lipopolysaccharide-induced neuroinflammation. <i>Glia</i> , 2022 , 70, 155-172	9	2
15	Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3107-8	2.2	1
14	Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme. <i>Nutrition and Cancer</i> , 2016 , 68, 926-34	2.8	1
13	Magnetic resonance cisternography in the diagnosis of delayed iatrogenic cerebrospinal fistula: a case report 1997 , 7, 244-7		1
12	Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2021-2021	2.2	1
11	ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. <i>Neuro-Oncology</i> , 2018 , 20, vi15-vi15	1	1
10	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vdab186	0.9	1
9	Mitochondrial DNA sequence variation and risk of meningioma. <i>Journal of Neuro-Oncology</i> , 2021 , 155, 319-324	4.8	0
8	Complications from pharmacotherapy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 235-50	3	0
7	Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics. <i>Neuro-Oncology</i> , 2020 , 22, 1713-1714	1	
6	Primary Melanotic Tumors of the Central Nervous System 2012 , 709-714		
5	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2003-2003	2.2	
4	Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2033-2033 ^{2,2}		
3	Digital measurement of functional status of patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2016-2016	2.2	
2	Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populations-An Exemplar in Brain Tumors. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 985-994 ^{5,2}		
1	High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.. <i>Journal of Neuro-Oncology</i> , 2022 , 1	4.8	